Paradigm Biopharmaceuticals (ASX:PAR) Total Assets: A$23.15 Mil (As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
28 GF Score
Price A$0.17
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Total Assets?

Paradigm Biopharmaceuticals ASX:PAR 28 Total Assets is A$23.15 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Paradigm Biopharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was A$23.15 Mil.

During the past 12 months, Paradigm Biopharmaceuticals's average Total Assets Growth Rate was -19.70% per year. During the past 3 years, the average Total Assets Growth Rate was -11.00% per year. During the past 5 years, the average Total Assets Growth Rate was -4.40% per year.

During the past 10 years, Paradigm Biopharmaceuticals's highest 3-Year average Total Assets Growth Rate was 18.20%. The lowest was -11.60%. And the median was -10.40%.

Total Assets is connected with ROA %. Paradigm Biopharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 was -194.82%. Total Assets is also linked to Revenue through Asset Turnover. Paradigm Biopharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Paradigm Biopharmaceuticals  (ASX:PAR) Total Assets Explanation

Total Assets is connected with ROA %.

Paradigm Biopharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-46.488/( (24.572+23.153)/ 2 )
=-46.488/23.8625
=-194.82 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Paradigm Biopharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0.025/( (24.572+23.153)/ 2 )
=0.025/23.8625
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Paradigm Biopharmaceuticals Total Assets Related Terms

Paradigm Biopharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Total Assets Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 84.90 50.69 67.07 27.39 24.57

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.04 27.39 35.36 24.57 23.15
ASX:PAR
28GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Paradigm Biopharmaceuticals's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (A: Jun. 2025 )+Total Liabilities (A: Jun. 2025 )
=21.184+3.387
=24.57

Paradigm Biopharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=5.998+17.155
=23.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of A$23.15 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Total Assets of A$23.15 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Paradigm Biopharmaceuticals and its competitors.
Is Paradigm Biopharmaceuticals' Total Assets too high?
Paradigm Biopharmaceuticals' current Total Assets is A$23.15 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Total Assets compare to VRTX and REGN?
Paradigm Biopharmaceuticals' Total Assets of A$23.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Total Assets is A$23.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Total Assets of A$23.15 Mil. The current Total Assets is A$23.15 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Total Assets is A$23.15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
28GF Score

Get the complete analysis for ASX:PAR

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.17
Price